Risky Business: PD-1 Immune Checkpoint Blockade in Thymic Epithelial Neoplasms

from Journal of Clinical Oncology (JCO) Podcast · host Jonathan W. Riess

This podcast discusses the important risks and potential benefits of PD-1 immune checkpoint blockade in patients with thymic epithelial neoplasms. Read the related article "Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial" on JCO.org

Episode metadata supplied by the publisher feed · Published Jun 18, 2018

Embed this episode

Attribution link and audio player

NOW PLAYING

Risky Business: PD-1 Immune Checkpoint Blockade in Thymic Epithelial Neoplasms

0:00 8:40

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Journal of Clinical Oncology (JCO) Podcast?

This episode is 8 minutes long.

When was this Journal of Clinical Oncology (JCO) Podcast episode published?

This episode was published on June 18, 2018.

Can I download this Journal of Clinical Oncology (JCO) Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!